Eledon Pharmaceuticals, Inc. — Director's Dealing 2014

Sep 17, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tokai Pharmaceuticals Inc (TKAI)
CIK: 0001404281
Period of Report: 2014-09-16

Reporting Person: McBride John S. (Chief Operating Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$4.19	2024-02-25	Common Stock (209178)		Direct

Footnotes

F1: This option was granted on February 25, 2014, with 12.5% of the shares underlying the option vesting on April 1, 2014 and an additional 2.0833% vesting on the first day of each month thereafter.